FDA Approves NovoLog(R) Labeling Update - Increasing The Time Patients Can Use And Store NovoLog(R) In Their Pumps From Two Days To Six Days
FDA Approves NovoLog(R) Labeling Update - Increasing The Time Patients Can Use And Store NovoLog(R) In Their Pumps From Two Days To Six Days
Diabetes patients taking NovoLog® (insulin aspart [rDNA origin] injection) can now use the insulin in their pump for up to six days following the U.S. Food and Drug Administration (FDA) approval of a labeling change, diabetes care company Novo Nordisk announced today.[i] The previous label allowed for NovoLog® to be stored in the pump reservoir for two days. This makes NovoLog® the first and only rapid-acting insulin with this extended in-use time.